CALL US

News

Schulman IRB’s Institutional Biosafety Committee (IBC) Service to Launch in May

April 25th, 2017

Schulman IRB announced today that its commercial institutional biosafety committee (IBC) service will launch in May 2017.

The IBC service represents Schulman’s response to requests from research sponsors, CROs and institutions seeking an independent option for establishing IBCs when required by federal guidelines.

Led by Dr. Daniel Eisenman, Ph.D., RBP, SM(NRCM), CBSP, the IBC service provides comprehensive support for research sponsors and sites conducting research involving recombinant DNA (genetic engineering). Schulman’s commercial IBC service will support clinical, pre-clinical and non-clinical research, providing all components to complement an existing IBC or build and administer an entirely new IBC.

“Clinical trials involving recombinant DNA are becoming more common, especially in oncology,” said Michael Woods, President and CEO of Schulman IRB. “The IBC service will compliment and coordinate with Schulman’s existing IRB services, providing the expertise and efficiencies necessary to help clients conduct this research safely and expediently.”

NIH Guidelines require both IRB and IBC review for gene therapy (human gene transfer) research that receives NIH funding or takes place at NIH funded sites. The IBC reviews safety aspects of research involving recombinant DNA (genetic engineering), including risks associated with genetic modifications and experimental procedures as well as occupational and environmental safety.

BACK TO NEWS